Latest News

Endotronix News

FDA Approval for Endotronix Pivotal Trial

1st August 2019

Dublin, Ireland and LISLE, IL, USA – AUGUST 1, 2019 – Seroba’s portfolio company, Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced it has received conditional Investigational Device […]

Read More
Quanta News

Quanta Raises $48 million in Series C Funding Round

29th July 2019

Alcester, Warwickshire, UK, 29 July 2019.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announced that […]

Read More
Endotronix News

Endotronix Enrolls 1st Patient in SIRONA II CE Mark Trial

16th July 2019

LISLE, IL – JULY 15, 2019 – Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced enrollment of the first patient in its prospective, multi-center, SIRONA II trial, in Europe.  […]

Read More
Home V2

Seroba Invests in Storm Therapeutics

20th May 2019

20 May 2019.  STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that it has raised an additional £14 million bringing its total Series A financing to £30 million. The financing includes funding […]

Read More
Quanta SC+

Quanta SC+ confirmed as safe and easy to use

15th April 2019

Alcester, Warwickshire, UK, 15 April 2019.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announced that […]

Read More
Fusion

Fusion Raises $105m in Series B Financing

2nd April 2019

April 2nd 2019. Hamilton, Canada and Dublin, Ireland.  Seroba’s portfolio company, Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new […]

Read More
Jen Moderator Session On Investment Cycles

VCs with €6Bn in Funds to Invest Visit Dublin

28th March 2019

The sixth annual MedTech Strategist Innovation Summit Dublin will take place this April in the Shelbourne Hotel. Dozens of Venture Capital firms whose funds together amount to over €6 billion will attend the Summit, which is expected to attract some […]

Read More
Fusion News

First Patient Dosed in Fusion Phase I trial

19th February 2019

Boston, Massachusetts & Hamilton, Ontario. February 19, 2019.  Seroba portfolio company, Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (targeted alpha therapeutics) has announced the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate […]

Read More
Labcyte News Logo

Labcyte Sold to Beckman Coulter

30th January 2019

Dublin, Ireland. 30 January 2019. Seroba portfolio company, Labcyte, has been acquired by Beckman Coulter Life Sciences, part of the larger Danaher Corporation which generates approximately $6.5 billion in annual revenue. Labcyte is best known for its Echo® acoustic droplet ejection […]

Read More
Pq Bypass

PQ Bypass Announces $60M Financing

8th January 2019

PQ Bypass Announces $60 Million Financing to Advance New Therapeutic Approach to Peripheral Arterial Disease. Funds Will Support Pivotal Trial of Novel DETOUR System Designed for Patients with Tough to Treat Long Blockages in Leg Arteries. January 08, 2019. Ireland […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top